Yes, and as I've said, a simple means to assess efficacy of LL is to track both potassium and Free Thyroxine T4 every 3 months. Only when both of these biomarker/labs fail to increase from one period to the next should LL be stopped because when both fail to increase, LL is no longer functional because the patient's condition has improved so much that the giving of LL has essentially become equal to the giving of Placebo causing no effect on liver steatosis or fibrosis.

Therefore, for that matter, give it to the NAS 1 patients as well, but just get feedback with these 2 simple labs to determine whether or not to continue.